Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
American Cancer Society, Inc.
Avon Foundation
Cancer Treatment Research Foundation
The Commonwealth Fund
Genentech, Inc.
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00399529
First received: November 13, 2006
Last updated: December 11, 2012
Last verified: December 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2010
  Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: November 29, 2012